Association of serum lipoprotein-associated phospholipase A2 level with nonalcoholic fatty liver disease
Metabolic Syndrome and Related Disorders, cilt.10, sa.2, ss.103-109, 2012 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 10 Sayı: 2
- Basım Tarihi: 2012
- Doi Numarası: 10.1089/met.2011.0111
- Dergi Adı: Metabolic Syndrome and Related Disorders
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.103-109
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most common causes of chronic liver disease, worldwide. Lipoprotein-associated phospholipase A2 (Lp-PLA2) was recently characterized as a novel inflammatory biomarker that is correlated with several components constituting the metabolic syndrome. Methods: In this study, we determined the serum levels of Lp-PLA2 in patients with definite nonalcoholic steatohepatitis (NASH, n=25), borderline NASH (n=22), simple fatty liver (n=10), and healthy controls without evidence of liver disease (n=38). The levels of Lp-PLA2 were measured by enzyme-linked immunosorbent assay and compared in the four study groups. Moreover, concentrations of Lp-PLA2 were assessed in relation to the general characteristics of the study participants and the results of liver biopsy. Results: Concentrations of Lp-PLA2 were significantly higher in patients with definite NASH (161.8±0.9μg/L, P<0.001), borderline NASH (135.4±47.7μg/L, P=0.001), and simple fatty liver (132.4±46. 2μg/L, P=0.042) compared with healthy controls (86.2±40.7μg/L). Furthermore, the serum Lp-PLA2 level was strongly associated to histological steatosis scores in patients with NAFLD (β=0.32, t=2.50, P=0.016). Conclusion: Although subject to future confirmation, our data suggest that Lp-PLA2 levels are elevated in NAFLD. © Copyright 2012, Mary Ann Liebert, Inc.